Hostname: page-component-848d4c4894-8bljj Total loading time: 0 Render date: 2024-06-14T21:34:36.694Z Has data issue: false hasContentIssue false

Escitalopram in patients with psoriasis

Published online by Cambridge University Press:  13 August 2021

M. Artemieva
Affiliation:
Psychiatry And Medical Psychology, RUDN University, Moscow, Russian Federation
I. Danilin*
Affiliation:
Psychiatry And Medical Psychology, RUDN University, Moscow, Russian Federation
Z. Ziewozinska
Affiliation:
Dermatology And Venereology, Pirogov Russian National Research Medical University, Moscow, Russian Federation
R. Suleimanov
Affiliation:
Psychiatry And Medical Psychology, RUDN University, Moscow, Russian Federation
A. Lazukova
Affiliation:
Psychiatry And Medical Psychology, RUDN University, Moscow, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Psoriasis is a chronic skin disease, affecting up to 2-4% of population. The majority of investigations agree that this disease appears to be a result of confluence of genetic, allergenic and emotional factors. There is usually more than one trigger that leads to the manifestation or exacerbation of symptoms. Psychogenic factors are clearly in a pattern here. Some personality traits may lead to instability of the emotional sphere that can act alternately as a cause, then as an aftereffect of exacerbation of the chronic process, forming a so called “vicious circle” of psychosomatic disease.

Objectives

To discover the impact of escitalopram on the symptoms of psoriasis.

Methods

14 patients were diagnosed with psoriasis. All patients underwent psychiatric interviewing and psychological testing (STAI and HADS). The results revealed increased trait anxiety levels among 8 of them with moderate severity of the process according to SCORAD index. 3 cases demonstrated symptoms of clinically expressed and 4 subclinical levels of depression. Escitalopram (10 to 20 mg. daily) was administered along with common dermatologic therapy in these patients.

Results

Patients treated with escitalopram showed a reduction of anxiety and depression tests scores as well as the values some dermatological symptoms such as pruritus.

Conclusions

These preliminary results of 3 months study gives us a hope of successful psychopharmacological treatment of psoriasis in cooperation with dermatologists. Finding intercommunications in pathogenesis of skin and emotional disorders could optimize the treatment and improve patient’s quality of life. The publication was prepared with the support of the “RUDN University Program 5-100”.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.